Dynamic contrast-enhanced MRI: Use in predicting pathological complete response to neoadjuvant chemoradiation in locally advanced rectal cancer Journal Article


Authors: Tong, T.; Sun, Y.; Gollub, M. J.; Peng, W.; Cai, S.; Zhang, Z.; Gu, Y.
Article Title: Dynamic contrast-enhanced MRI: Use in predicting pathological complete response to neoadjuvant chemoradiation in locally advanced rectal cancer
Abstract: Purpose To determine the ability of dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) to predict pathological complete response (pCR) before preoperative chemoradiotherapy (CRT) in locally advanced rectal cancer. Materials and Methods In a prospective clinical trial, 38 enrolled patients underwent pre- and post-CRT DCE-MRI at 3.0T. The tumor length and the following perfusion parameters (Ktrans, k<inf>ep</inf>, v<inf>e</inf>) were measured for the tumor and compared between the pCR group and the non-pCR group, as well as before and after CRT. For categorical variable comparison, the Kruskal-Wallis test was used. P<0.05 was considered significant. Results No difference in tumor length was found between the pCR and non-pCR group pre- and post-CRT (P=0.26 (0.15,0.45), 0.35 (0.21,0.52), respectively). Before CRT, the mean tumor Ktrans in the pCR group was significantly higher than in the non-pCR group (P=0.01). A Ktrans of 0.66 emerged as the best cutoff for distinguishing pCR from non-pCR. Regarding k<inf>ep</inf> and v<inf>e</inf>, significant differences were also observed between the pCR and non-pCR groups (P=0.02, 0.01, respectively). The mean Ktrans, k<inf>ep</inf>, and v<inf>e</inf> values post-CRT were lower in the pCR group than in the non-pCR group, although there was no significant difference (P=0.10 (0.04,0.16), 0.11 (0.07,0.26), 0.10 (0.06,0.23), respectively). Conclusion Before neoadjuvant chemoradiotherapy in rectal cancer, DCE-MRI can distinguish between complete and incomplete response using a Ktrans threshold of 0.66 with a sensitivity of 100%. J. Magn. Reson. Imaging 2015;42:673-680. © 2015 Wiley Periodicals, Inc.
Keywords: adult; clinical article; controlled study; human tissue; treatment outcome; treatment response; aged; histopathology; advanced cancer; capecitabine; cancer adjuvant therapy; preoperative care; radiation dose; cancer staging; nuclear magnetic resonance imaging; prospective study; sensitivity analysis; controlled clinical trial; tumor volume; cohort analysis; prediction; pilot study; contrast enhancement; cancer classification; oxaliplatin; rectum cancer; dce-mri; chemoradiotherapy; rectum surgery; rectal cancer; nuclear magnetic resonance scanner; radiological parameters; complete pathological response; human; male; female; priority journal; article
Journal Title: Journal of Magnetic Resonance Imaging
Volume: 42
Issue: 3
ISSN: 1053-1807
Publisher: Wiley Blackwell  
Date Published: 2015-09-01
Start Page: 673
End Page: 680
Language: English
DOI: 10.1002/jmri.24835
PROVIDER: scopus
PUBMED: 25652254
DOI/URL:
Notes: Export Date: 2 September 2015 -- Source: Scopus
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Marc J Gollub
    209 Gollub